About Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.

The company was founded in 2015 by Max Krummel, Ph.D., a professor at University of California, San Francisco School of Medicine (UCSF), who has been making significant strides in immuno-oncology since the mid-1990s. Dr. Krummel is the co-inventor of YERVOY® (ipilimumab), the first checkpoint inhibitor, which was approved in 2011 to treat melanoma. Pionyr has exclusively licensed technology from UCSF based on Dr. Krummel’s work.

In 2020, Pionyr entered a transformational alliance with Gilead Sciences (read more) ahead of receiving IND clearance for its two lead programs PY314 and PY159.

Pionyr’s Path

2015

Pionyr Founded

2015

$1.3M Series A Funding

2016

$8M Series A-1 OrbiMed, SV, Osage, Mission Bay

2016

4 TME-Targeted mABs in Process

2016

18 Employees

2016

Located at MBC BioLabs

2017

$69M Series B NEA, Sofinnova, Vida, Trinitas + Prior Investors

2018

New Labs at Genesis Towers, 40+ Employees

2020

Pionyr/Gilead Alliance

2020

PY314 into P1 and PY159 with IND achieved

Leadership

Steven P. James photo

Steven P. James / President and CEO

Michel Streuli, PhD photo

Michel Streuli, PhD / Senior Vice President and Chief Scientific Officer

Leonard Reyno, MD photo

Leonard Reyno, MD / Senior Vice President and Chief Medical Officer

Monte Montgomery photo

Monte Montgomery / Senior Vice President and Chief Financial Officer

Alicia Levey, PhD photo

Alicia Levey, PhD / Senior Vice President and Chief Business Officer

Kevin Baker, PhD photo

Kevin Baker, PhD / Senior Vice President, Preclinical Sciences and Program Management

Evan Greger photo

Evan Greger, MSA, MS / Senior Vice President, Technical Operations

Lisa Stemmerich photo

Lisa Stemmerich, MBA / Vice President, Human Resources

Venkataraman Sriram photo

Venkataraman Sriram, PhD / Vice President, ImmunoPharmacology & Early Development

Board of Directors

Rishi Gupta, JD / OrbiMed

Steven P. James / President and CEO, Pionyr Immunotherapeutics

Max Krummel, PhD / Robert E. Smith Endowed Chair in Experimental Pathology, UCSF

Mike Powell, PhD / Sofinnova

Michael Quigley, PhD / Senior Vice President of Research Biology, Gilead Sciences

Mike Ross, PhD / SV Health Investors

Scientific Advisory Board

Max Krummel, PhD (Chair) / Professor, Department of Pathology, UCSF

Chloe Atreya, MD, PhD / Assistant Clinical Professor, Department of Medicine, UCSF

Miriam Merad, MD, PhD / Professor of Oncological Science, Medicine and Immunology and a member of the Immunology Institute and The Tisch Cancer Institute, Mount Sinai School of Medicine

Stephen Hodi, MD / Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute

Investors & Partners

gilead logo

nea logo

orbimed logo

sofinnova logo

sv health investors logo

vida ventures logo

osage logo

mission bay capital logo

trinitas capital logo